Congenital Heart Defects: Could the Developing Heart Hold the Key to New Therapies?

submitted by: mcgheek

Andrew M. Atz, M.D., Chief of the Division of Pediatric Cardiology at MUSC's Children's Hospital, and Kyu-Ho Lee, M.D., PhD, a developmental biologist at MUSC's Cardiovascular Developmental Biology Center, discuss how better understanding the gene signaling involved in the embryonic development of the heart could lead to new adjunctive therapies for congenital heart defects. Learn more about Dr. Lee's work in the November 2013 issue of Progressnotes at

Atrial Septal Defect

submitted by: drguilleortiz

Small defects (<5mm) usually doesnt affect patient natural history, therefore not required limitations on life or excercise. This type of ocassional findings in TTE required forward evaluation of: 1) Associate valvular disease, 2) Paradoxical embolism, 3) Pulmonary hypertension (>30 mmHG), Arrythmia (atrial fibrillation) or symptoms that indicate the possibility of therapeutic closure of the defect.

Nematic Colloids

submitted by: icamvid

Ivan Smalyukh gives a talk at the LC2CAM 08 conference about nematic colloids, how they are bound, methods of assembly, localized defects, and exotic assembly.